These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

915 related items for PubMed ID: 12460903

  • 1. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors.
    Hagedorn M, Zilberberg L, Wilting J, Canron X, Carrabba G, Giussani C, Pluderi M, Bello L, Bikfalvi A.
    Cancer Res; 2002 Dec 01; 62(23):6884-90. PubMed ID: 12460903
    [Abstract] [Full Text] [Related]

  • 2. Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF.
    Jia H, Jezequel S, Löhr M, Shaikh S, Davis D, Soker S, Selwood D, Zachary I.
    Biochem Biophys Res Commun; 2001 Apr 27; 283(1):164-73. PubMed ID: 11322784
    [Abstract] [Full Text] [Related]

  • 3. A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2.
    Hagedorn M, Zilberberg L, Lozano RM, Cuevas P, Canron X, Redondo-Horcajo M, Gimenez-Gallego G, Bikfalvi A.
    FASEB J; 2001 Mar 27; 15(3):550-2. PubMed ID: 11259363
    [Abstract] [Full Text] [Related]

  • 4. The COOH-terminal peptide of platelet factor-4 variant (CXCL4L1/PF-4var47-70) strongly inhibits angiogenesis and suppresses B16 melanoma growth in vivo.
    Vandercappellen J, Liekens S, Bronckaers A, Noppen S, Ronsse I, Dillen C, Belleri M, Mitola S, Proost P, Presta M, Struyf S, Van Damme J.
    Mol Cancer Res; 2010 Mar 27; 8(3):322-34. PubMed ID: 20215425
    [Abstract] [Full Text] [Related]

  • 5. Studies on the structure-activity relationship of endostatin: synthesis of human endostatin peptides exhibiting potent antiangiogenic activities.
    Chillemi F, Francescato P, Ragg E, Cattaneo MG, Pola S, Vicentini L.
    J Med Chem; 2003 Sep 11; 46(19):4165-72. PubMed ID: 12954068
    [Abstract] [Full Text] [Related]

  • 6. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.
    Cancer Res; 2003 Sep 15; 63(18):5978-91. PubMed ID: 14522925
    [Abstract] [Full Text] [Related]

  • 7. The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization.
    Olsson AK, Johansson I, Akerud H, Einarsson B, Christofferson R, Sasaki T, Timpl R, Claesson-Welsh L.
    Cancer Res; 2004 Dec 15; 64(24):9012-7. PubMed ID: 15604266
    [Abstract] [Full Text] [Related]

  • 8. Recent developments in the inhibition of angiogenesis: examples from studies on platelet factor-4 and the VEGF/VEGFR system.
    Bikfalvi A.
    Biochem Pharmacol; 2004 Sep 15; 68(6):1017-21. PubMed ID: 15313395
    [Abstract] [Full Text] [Related]

  • 9. Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth.
    Fahmy RG, Dass CR, Sun LQ, Chesterman CN, Khachigian LM.
    Nat Med; 2003 Aug 15; 9(8):1026-32. PubMed ID: 12872165
    [Abstract] [Full Text] [Related]

  • 10. Goniodomin A, an antifungal polyether macrolide, exhibits antiangiogenic activities via inhibition of actin reorganization in endothelial cells.
    Abe M, Inoue D, Matsunaga K, Ohizumi Y, Ueda H, Asano T, Murakami M, Sato Y.
    J Cell Physiol; 2002 Jan 15; 190(1):109-16. PubMed ID: 11807817
    [Abstract] [Full Text] [Related]

  • 11. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.
    Cheng N, Brantley DM, Liu H, Lin Q, Enriquez M, Gale N, Yancopoulos G, Cerretti DP, Daniel TO, Chen J.
    Mol Cancer Res; 2002 Nov 15; 1(1):2-11. PubMed ID: 12496364
    [Abstract] [Full Text] [Related]

  • 12. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
    Kim CK, Joe YA, Lee SK, Kim EK, O E, Kim HK, Oh BJ, Hong SH, Hong YK.
    Cancer Lett; 2010 Feb 28; 288(2):251-60. PubMed ID: 19664879
    [Abstract] [Full Text] [Related]

  • 13. Metastatin: a hyaluronan-binding complex from cartilage that inhibits tumor growth.
    Liu N, Lapcevich RK, Underhill CB, Han Z, Gao F, Swartz G, Plum SM, Zhang L, Green SJ.
    Cancer Res; 2001 Feb 01; 61(3):1022-8. PubMed ID: 11221828
    [Abstract] [Full Text] [Related]

  • 14. Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin.
    Morbidelli L, Donnini S, Chillemi F, Giachetti A, Ziche M.
    Clin Cancer Res; 2003 Nov 01; 9(14):5358-69. PubMed ID: 14614021
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3.
    Anand-Apte B, Pepper MS, Voest E, Montesano R, Olsen B, Murphy G, Apte SS, Zetter B.
    Invest Ophthalmol Vis Sci; 1997 Apr 01; 38(5):817-23. PubMed ID: 9112976
    [Abstract] [Full Text] [Related]

  • 16. The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects.
    Béliveau R, Gingras D, Kruger EA, Lamy S, Sirois P, Simard B, Sirois MG, Tranqui L, Baffert F, Beaulieu E, Dimitriadou V, Pépin MC, Courjal F, Ricard I, Poyet P, Falardeau P, Figg WD, Dupont E.
    Clin Cancer Res; 2002 Apr 01; 8(4):1242-50. PubMed ID: 11948139
    [Abstract] [Full Text] [Related]

  • 17. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
    Sun J, Blaskovich MA, Jain RK, Delarue F, Paris D, Brem S, Wotoczek-Obadia M, Lin Q, Coppola D, Choi K, Mullan M, Hamilton AD, Sebti SM.
    Cancer Res; 2004 May 15; 64(10):3586-92. PubMed ID: 15150116
    [Abstract] [Full Text] [Related]

  • 18. Antiangiogenic effects of latent antithrombin through perturbed cell-matrix interactions and apoptosis of endothelial cells.
    Larsson H, Sjöblom T, Dixelius J, Ostman A, Ylinenjärvi K, Björk I, Claesson-Welsh L.
    Cancer Res; 2000 Dec 01; 60(23):6723-9. PubMed ID: 11118058
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist.
    Kumar CC, Malkowski M, Yin Z, Tanghetti E, Yaremko B, Nechuta T, Varner J, Liu M, Smith EM, Neustadt B, Presta M, Armstrong L.
    Cancer Res; 2001 Mar 01; 61(5):2232-8. PubMed ID: 11280792
    [Abstract] [Full Text] [Related]

  • 20. Cysteine-rich and basic domain HIV-1 Tat peptides inhibit angiogenesis and induce endothelial cell apoptosis.
    Jia H, Lohr M, Jezequel S, Davis D, Shaikh S, Selwood D, Zachary I.
    Biochem Biophys Res Commun; 2001 May 04; 283(2):469-79. PubMed ID: 11327725
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.